A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypes
- Conditions
- Angina pectoris and myocardial infarction
- Registration Number
- JPRN-UMIN000003898
- Lead Sponsor
- ational Cerebral and Cardiovascular Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 150
Not provided
1) the patient of severe liver disease 2) the patient of severe renal disease 3) the patient of congenital heart disease 4) the patient of myocardial infarction within 3 months from onset or of severe cardiac function 5) the patient of endocrine disease 6) the patient of malignant or inflammatory disease 7) the patient of severe respiratory disease including idiopathic pulmonary artery hypertension 8) the patient of impaired activities of daily living by neurological or orthopedic disease 9) the patient of severe hypertension 10) the patient who taking corticosteroid or immunosuppressive drug 11) the patient of type 1 diabetes mellitus 12) the patient pregnant or probable of pregnancy 13) the catecholamine injected patient 14) the patient of symptomatic hypotension 15) the patient with left ventricular outflow tract obstruction, hypertrophic obstructive cardiomyopthy or aortic stenosis, effecting hemodynamics significantly 16) the patient who is judged inappropriate for any reason by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inhibitory effect of anti-platelet aggregation estimated by phosphorytation of VASP after administration of clopidgrel and proton pump inhibitors
- Secondary Outcome Measures
Name Time Method relationship between CYP2C19 genotypes and the effect of proton pump inhibitors on anti-platelet aggregation by clopidgrel